Best of the Week
Most Popular
1.UK House Prices BrExit Crash NOT Likely Despite London Property Market Weakness - Nadeem_Walayat
2.BrExit Morning - New Dawn for Britain, Independence Day! - Nadeem_Walayat
3.LEAVE Wins EU Referendum - Sterling and FTSE Hit Hard, Pollsters, Bookies and Markets All WRONG! - Nadeem_Walayat
4.BrExit Implications for UK Stock Market, Sterling GBP, House Prices and UK Politics... - Nadeem_Walayat
5.Trading BrExit - Stocks, Bonds, Sterling, Opinion Polls, Bookmaker Odds and My Forecast - Nadeem_Walayat
6.FTSE and Sterling Brexit Trading, Deconstruction of the EU Referendum Result - Nadeem_Walayat
7.UK Interest Rate Cut to 0.25% Imminent and More QE Money Printing - Nadeem_Walayat
8.Trading BrExit - British Pound Plunges, FTSE Stock Futures Slump on LEAVE Shock Referendum Win - Nadeem_Walayat
9.The Stock Market is Reading it Wrong! - Chris_Vermeulen
10.Breakouts Galore in Gold and Silver - Jordan_Roy_Byrne
Free Silver
Last 7 days
Bitcoin $650 Still in Play - 26th July 16
Deutche Bank Stock Price Crash - The EU Has Problems Far Beyond the Brexit - 26th July 16
The Forex Markets Are Getting Exciting! - 26th July 16
Underpriced Silver Is the “Rip Van Winkle” Metal - 25th July 16
Declines in Multiple Market Indexes - 25th July 16
Retailers Are Doomed as Most Americans Are Too Poor to Shop - 25th July 16
Here’s One Currency That Could Go to Zero - 25th July 16
Stock Market Top is Expanding - 25th July 16
Silver Manipulation – Because They Needed the Eggs - 25th July 16
Silver Market COT Stuns: What's Going On Here? - 24th July 16
Gold Demand Remains Stable During Sector Weakness - 24th July 16
Sernova, Diabetes and Haemophilia - 24th July 16
Russia: Tensions, Turmoil, and Western Hubris - 24th July 16
Soybean Commodity Price to Soar Again - 23rd July 16
SPX Stock Market Uptrend Continues - 23rd July 16
Gold And Silver – Debt Addiction Will Carry Precious Metals Higher, Guaranteed - 23rd July 16
Pokemon Go - How to Play, First Use, Balls, Stops, Catching Pokemon's... Great Excercise! - 23rd July 16
7 Signs That the Gold Market Remains Resilient - 23rd July 16
Basic Income in The Time of Crisis - 23rd July 16
Silver Bull Faces Correction - 22nd July 16
The Serious Warning No One’s Talking About - 22nd July 16
Stock Market Insight from Greed, Volatility, and Put/Call Ratio - 22nd July 16
What Will Happen To the Stock Market When Interest Rates Rise? - 22nd July 16
How to Escape the World’s Biggest Ponzi Scheme - 22nd July 16
Addicted to Debt - We Can’t Borrow from the Future Anymore - 21st July 16
Not Everything Is Bullish for Gold - 21st July 16
Don’t Get Sucked Back Into the Stock Market - The Big Picture Hasn’t Changed - 21st July 16
Silver – Caught Inside - 21st July 16
Forex: "The Markets Are Getting Exciting!" - 20th July 16
China Economic Troubles - Is Kyle Bass Finally Getting His Revenge? - 20th July 16
Why Lithium Will See Another Price Spike This Fall - 20th July 16
The Peak Oil Paradox Revisited - 19th July 16
SPX Challenges the Upper Trendline - 19th July 16
Missing ’28 Pages’ of the 9/11 Report Released into Blitzkrieg of World Events - 19th July 16
Likelihood of Organized Disruption at GOP Convention - 19th July 16
More on the ‘Breadth Thrust’ and Stock Market Internals - 19th July 16
FX Traders: Get a Free Week of Forecasts (Details inside) - 19th July 16
Ups and Downs in Gold and Crude Oil Price - 19th July 16
Keep an Eye on ‘Bitcoin’ as the Next ‘Financial Crisis’ Starts! - 18th July 16
Erdogan Might Have Known about the Coup but Didn’t Prevent It on Purpose - 18th July 16
More Deflation Ahead: Silver, Gold And Their Mining Stocks A Must-Have - 18th July 16
Stock Market Minor Top? - 18th July 16

Free Instant Analysis

Free Instant Technical Analysis


Market Oracle FREE Newsletter

The Power of the Wave Principle

Biotech Stocks to Buy Now

Companies / BioTech Nov 15, 2012 - 09:35 AM GMT

By: Money_Morning

Companies

Best Financial Markets Analysis ArticleDon Miller writes: If you're looking to hit a home run over the next 12 months, your best bet for stocks to buy now is biotechnology companies - especially those focused on cancer research.

Here's why: biotech stocks have been in a stealth bull market in 2012.


In fact, the values of the 230 publicly-traded biotech companies tracked by the BioWorld Stock Report have jumped by an average 38% year-to-date.

The third quarter was especially hot. The Nasdaq Biotechnology Index rose 10% over that time frame and is up a healthy 37% this year.

And, nothing is hotter than companies focused on the battle against cancer.

Take Medivation Inc. (Nasdaq: MDVN), for example. This California-based biotech has jumped from $23 to $46 a share, largely on the approval of Xtandi, its novel prostate cancer drug.

Thousands of other experimental drugs are going through various stages of clinical trials, and the largest category in the pipeline is cancer drugs. With that in mind, it's safe to say that if you're looking for a stock with big upside potential, cancer-driven biotech stocks should be high on your list. Biotech Stocks: Cancer Research is Paying Off

A cancer diagnosis was once a death sentence -- especially if you were diagnosed with the disease in its late stages.

But, both government and industry have spent vast sums in the last decade researching how cancers develop and spread.

And now all that investment is starting to pay off -- recent clinical trials and treatment breakthroughs show real promise.

The newest cancer research focuses on three fronts.

•Finding ways to boost the ability of the body's own immune system to recognize and kill malignant cells.
•Identifying unique characteristics of cancer cells and aiming drugs to destroy only those cells - as opposed to traditional chemotherapy, which kills healthy cells, too.
•Blocking the pathways used by cancer cells to spread throughout the body and killing the trapped cells before they escape and multiply.
These revolutionary new therapies have given patients renewed hope -- and investors good reasons to bid up shares of biotech companies that specialize in cancer cures.

Three Phases of Drug Testing
The value of a company that's working on cancer cures hinges on how its drugs progress through clinical trials.

The Food and Drug Administration (FDA) requires drug makers to navigate a three-stage testing process to prove a drug's safety and effectiveness.

New drugs are first tested on humans in Phase One trials to determine whether a drug is effective and if it has serious side effects.

Phase Two testing treats a specific illness in a larger group of patients at a predetermined dose level and measures how patients tolerate it.

Phase Three trials compare the benefits of the drug against existing treatments.

If the drug ultimately proves both effective and safe, the results are submitted to the FDA for approval.

Clinical trials are everything, since 95% of all new drugs never make it through clinical trials.

But as a drug successfully completes each trial, the odds of success rise. And analysts start to boost their values -- often by exponential amounts.

Still, almost anything can happen before a drug gets final regulatory approval.

"These are inherently risky assets," said analyst Geoffrey Porges of Bernstein Research.

Three Biotech Stocks to Buy Now
For investors, that presents both challenge and opportunity.

The failure of a single clinical trial can send both the company and its investors into a tailspin. Conversely, if a drug succeeds, a small company could suddenly have the potential to double in price overnight.

By focusing on biotech stocks with drug candidates headed into late stage clinical trials you can vastly increase your odds of finding a winner to buy now.

Here are three cancer-focused biotech stocks that experts feel are worth a look:

•Exelixis Inc. (Nasdaq: EXEL) is developing Cabozantinib, an inhibitor of tumor growth in the development and progression of various cancers. The drug is in Phase III trials for the treatment of thyroid cancer and also in clinical programs focused on the treatment of prostate, ovarian, breast cancer and melanoma. In addition, Exelixis is collaborating on additional therapies with heavy hitters like Bristol-Myers Squibb Co. (NYSE: BMY), Sanofi SA (ADR NYSE: SNY) and GlaxoSmithKline plc (ADR NYSE: GSK).

•ARIAD Pharmaceuticals, Inc.'s (Nasdaq: ARIA) Ridaforolimus is being studied in multiple clinical trials in patients with metastatic sarcomas, breast cancer, endometrial cancer, prostate cancer and lung cancer. The company has collaboration and license agreements with deep-pocketed Merck & Co. Inc. (NYSE: MRK) for the development, manufacture and commercialization of ridaforolimus and licenses to develop and commercialize stents and other medical devices to deliver the drug.
•And in June, the FDA approved Carfilzomib, the Onyx Pharmaceuticals Inc. (Nasdaq: ONXX) drug for multiple myeloma. According to analysts' estimates compiled by Bloomberg News, the drug could ring up annual sales of $523 million by 2016 -- more than doubling last year's revenues. Onyx is also involved in a partnership with Bayer AG (ADR PINK: BAYRY) with drugs that treat kidney and liver cancers.

As for a fourth, Private Briefing Editor Bill Patalon has discovered a biotech stock with a large, sudden and concentrated block of insider buying. In fact, these insiders just spent $353,000 on the purchase of nearly 215,000 shares of their company's stock.

According to Bill, this company is so strong its shares could jump by 295%.

To learn more about this company click here.

Source :http://moneymorning.com/2012/11/15/three-biotech-stocks-to-buy-now/

Money Morning/The Money Map Report

©2012 Monument Street Publishing. All Rights Reserved. Protected by copyright laws of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), of content from this website, in whole or in part, is strictly prohibited without the express written permission of Monument Street Publishing. 105 West Monument Street, Baltimore MD 21201, Email: customerservice@moneymorning.com

Disclaimer: Nothing published by Money Morning should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investent advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication, or after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended by Money Morning should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

Money Morning Archive

© 2005-2016 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in

Catching a Falling Financial Knife